Tags

Type your tag names separated by a space and hit enter

Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.
Clin Lymphoma Myeloma Leuk 2011; 11(3):298-302CL

Abstract

Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-κ type.(1) Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy. We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment.

Authors+Show Affiliations

Boston VA Healthcare System, Boston, MA, USA. Yvonne.efebera@osumc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

21658660

Citation

Efebera, Yvonne, et al. "Complete Response to Thalidomide and Dexamethasone in a Patient With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathy: a Case Report and Review of the Literature." Clinical Lymphoma, Myeloma & Leukemia, vol. 11, no. 3, 2011, pp. 298-302.
Efebera Y, Blanchard E, Allam C, et al. Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011;11(3):298-302.
Efebera, Y., Blanchard, E., Allam, C., Han, A., Lee, S., & Munshi, N. (2011). Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clinical Lymphoma, Myeloma & Leukemia, 11(3), pp. 298-302. doi:10.1016/j.clml.2011.03.020.
Efebera Y, et al. Complete Response to Thalidomide and Dexamethasone in a Patient With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathy: a Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2011;11(3):298-302. PubMed PMID: 21658660.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. AU - Efebera,Yvonne, AU - Blanchard,Elizabeth, AU - Allam,Charles, AU - Han,Andrew, AU - Lee,Saem, AU - Munshi,Nikhil, Y1 - 2011/04/20/ PY - 2010/10/07/received PY - 2010/12/17/revised PY - 2011/01/06/accepted PY - 2011/6/11/entrez PY - 2011/6/11/pubmed PY - 2011/10/4/medline SP - 298 EP - 302 JF - Clinical lymphoma, myeloma & leukemia JO - Clin Lymphoma Myeloma Leuk VL - 11 IS - 3 N2 - Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-κ type.(1) Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy. We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment. SN - 2152-2669 UR - https://www.unboundmedicine.com/medline/citation/21658660/Complete_response_to_thalidomide_and_dexamethasone_in_a_patient_with_necrobiotic_xanthogranuloma_associated_with_monoclonal_gammopathy:_a_case_report_and_review_of_the_literature_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(11)00021-8 DB - PRIME DP - Unbound Medicine ER -